Pharmacological Research (Aug 2023)

Targeting of HBP1/TIMP3 axis as a novel strategy against breast cancer

  • Yue Zhou,
  • Tongjia Zhang,
  • Shujie Wang,
  • Ruixiang Yang,
  • Zitao Jiao,
  • Kejia Lu,
  • Hui Li,
  • Wei Jiang,
  • Xiaowei Zhang

Journal volume & issue
Vol. 194
p. 106846

Abstract

Read online

Malignant proliferation and metastasis are the main causes of breast cancer death. The transcription factor high mobility group (HMG) box-containing protein 1 (HBP1) is an important tumor suppressor whose deletion or mutation is closely related to the appearance of tumors. Here, we investigated the role of HBP1 in breast cancer suppression. HBP1 enhances the activity of the tissue inhibitors of metalloproteinases 3 (TIMP3) promoter, thereby increasing protein and mRNA levels of TIMP3. TIMP3 increases the phosphatase and tensin homolog (PTEN) protein level by inhibiting its degradation and acts as a metalloproteinase inhibitor to inhibit the protein levels of MMP2/9. In this study, we demonstrated that the HBP1/TIMP3 axis plays a crucial role in inhibiting the tumorigenesis of breast cancer. HBP1 deletion interferes with the regulation of the axis and induces the occurrence and malignant progression of breast cancer. In addition, the HBP1/TIMP3 axis promotes the sensitivity of breast cancer to radiation therapy and hormone therapy. Our study opens new perspectives on the treatment and prognosis of breast cancer.

Keywords